X-Chem / Proteros Webinar

Supporting Your Search for Novel Chemical Equity and Qualified Hits


First-ever-reported inhibitors of BTK to utilize epoxides as electrophile: A case study in how to identify and validate drug-like leads for difficult-to-target drugs

July 20, 2021 | 11 a.m. EDT


During this webinar, leaders from DNA-encoded chemistry expert X-Chem and protein sciences specialist Proteros discussed:

  • How X-Chem and Proteros work together to identify and validate hits
    • From library design through to qualified hits
    • How they can enhance your drug discovery process
  • Drug target BTK case study
    • Developing a screen to detect covalent irreversible inhibitors to targets of therapeutic interest
    • First-ever-reported inhibitors of BTK to utilize epoxides as electrophile
    • The technologies, expertise and scientific insights that made these discoveries possible

Screenshot 2021-08-13 at 10.02.29
Anthony Keefe
Senior Vice President, Innovation
X-Chem, Inc.
Screenshot 2021-08-13 at 10.02.21
Debora Konz Makino 
Head of Discovery Solution 
Proteros biostructures GmbH

Please fill in the form below to request access to our on demand Webinar.